Characterization of a radiolabeled small molecule targeting leukocyte function-associated antigen-1 expression in lymphoma and leukemia

Rahul B. Poria, Jeffrey P. Norenberg, Tamara L. Anderson, Jack Erion, Carston R. Wagner, Jeffrey B. Arterburn, Richard S. Larson

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: Leukocyte function-associated antigen-1 (LFA-1) is constitutively expressed on leukocytes, including overexpression on lymphomas and leukemias. We have developed a derivative of BIRT 377, an allosteric inhibitor of LFA-1, which may be chemically tagged without affecting binding. In this study, we modified this derivative, (R)-1-(4-aminobutyl)-5-(4-bromobenzyl) -3-(3,5-dichlorophenyl)-5-methylimidazolidine-2,4-dione (butylamino-NorBIRT), and demonstrated its potential as a noninvasive imaging agent. Methods: Specific binding of fluorescein-labeled butylamino-NorBIRT to both human and murine cells was demonstrated using equilibrium binding and dissociation techniques. A radiometal, lutetium-177 (Lu-177), was incorporated into the butylamino-NorBIRT through 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA) as a chelator. Results: Equilibrium-binding experiments demonstrated that fluorescein-labeled butylamino-NorBIRT specifically binds human and murine LFA-1 with affinity constants of 135 and 186 nM, respectively. Dissociation kinetic experiments demonstrated an off-rate of 0.168/second -1 on murine cells, consistent with the observed affinity constant. Lutetium-177 was used for labeling, with ≥99.99% radiochemical purity and incorporation yield. This radiolabeled derivative exhibited high stability in fetal bovine serum (FBS) at 37°C over 72 hours. 177Lu-DOTA- butylamino-NorBIRT showed a binding affinity of 235 nM to human LFA-1 for equilibrium binding and competitive binding experiments. Conclusions: The radiolabeled DOTA-butylamino-NorBIRT may have potential as a noninvasive imaging or therapeutic agent in both human and mouse models.

Original languageEnglish (US)
Pages (from-to)418-426
Number of pages9
JournalCancer Biotherapy and Radiopharmaceuticals
Volume21
Issue number5
DOIs
StatePublished - Nov 20 2006

Fingerprint

Lymphocyte Function-Associated Antigen-1
Lymphoma
Leukemia
Lutetium
Fluorescein
Competitive Binding
Chelating Agents
Leukocytes
Serum
DOTA-1-(4-aminobutyl)-5-(4-bromobenzyl)-3-(3,5-dichlorophenyl)-5-methylimidazolidine-2,4-dione
Therapeutics

Keywords

  • Butylamino-NorBIRT
  • Leukocyte function-associated antigen-1
  • Lutetium-177
  • Lymphoma
  • Radionuclide imaging

Cite this

Characterization of a radiolabeled small molecule targeting leukocyte function-associated antigen-1 expression in lymphoma and leukemia. / Poria, Rahul B.; Norenberg, Jeffrey P.; Anderson, Tamara L.; Erion, Jack; Wagner, Carston R.; Arterburn, Jeffrey B.; Larson, Richard S.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 21, No. 5, 20.11.2006, p. 418-426.

Research output: Contribution to journalArticle

Poria, Rahul B. ; Norenberg, Jeffrey P. ; Anderson, Tamara L. ; Erion, Jack ; Wagner, Carston R. ; Arterburn, Jeffrey B. ; Larson, Richard S. / Characterization of a radiolabeled small molecule targeting leukocyte function-associated antigen-1 expression in lymphoma and leukemia. In: Cancer Biotherapy and Radiopharmaceuticals. 2006 ; Vol. 21, No. 5. pp. 418-426.
@article{031a6b15a499446790a8fa93562985a6,
title = "Characterization of a radiolabeled small molecule targeting leukocyte function-associated antigen-1 expression in lymphoma and leukemia",
abstract = "Objective: Leukocyte function-associated antigen-1 (LFA-1) is constitutively expressed on leukocytes, including overexpression on lymphomas and leukemias. We have developed a derivative of BIRT 377, an allosteric inhibitor of LFA-1, which may be chemically tagged without affecting binding. In this study, we modified this derivative, (R)-1-(4-aminobutyl)-5-(4-bromobenzyl) -3-(3,5-dichlorophenyl)-5-methylimidazolidine-2,4-dione (butylamino-NorBIRT), and demonstrated its potential as a noninvasive imaging agent. Methods: Specific binding of fluorescein-labeled butylamino-NorBIRT to both human and murine cells was demonstrated using equilibrium binding and dissociation techniques. A radiometal, lutetium-177 (Lu-177), was incorporated into the butylamino-NorBIRT through 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA) as a chelator. Results: Equilibrium-binding experiments demonstrated that fluorescein-labeled butylamino-NorBIRT specifically binds human and murine LFA-1 with affinity constants of 135 and 186 nM, respectively. Dissociation kinetic experiments demonstrated an off-rate of 0.168/second -1 on murine cells, consistent with the observed affinity constant. Lutetium-177 was used for labeling, with ≥99.99{\%} radiochemical purity and incorporation yield. This radiolabeled derivative exhibited high stability in fetal bovine serum (FBS) at 37°C over 72 hours. 177Lu-DOTA- butylamino-NorBIRT showed a binding affinity of 235 nM to human LFA-1 for equilibrium binding and competitive binding experiments. Conclusions: The radiolabeled DOTA-butylamino-NorBIRT may have potential as a noninvasive imaging or therapeutic agent in both human and mouse models.",
keywords = "Butylamino-NorBIRT, Leukocyte function-associated antigen-1, Lutetium-177, Lymphoma, Radionuclide imaging",
author = "Poria, {Rahul B.} and Norenberg, {Jeffrey P.} and Anderson, {Tamara L.} and Jack Erion and Wagner, {Carston R.} and Arterburn, {Jeffrey B.} and Larson, {Richard S.}",
year = "2006",
month = "11",
day = "20",
doi = "10.1089/cbr.2006.21.418",
language = "English (US)",
volume = "21",
pages = "418--426",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Characterization of a radiolabeled small molecule targeting leukocyte function-associated antigen-1 expression in lymphoma and leukemia

AU - Poria, Rahul B.

AU - Norenberg, Jeffrey P.

AU - Anderson, Tamara L.

AU - Erion, Jack

AU - Wagner, Carston R.

AU - Arterburn, Jeffrey B.

AU - Larson, Richard S.

PY - 2006/11/20

Y1 - 2006/11/20

N2 - Objective: Leukocyte function-associated antigen-1 (LFA-1) is constitutively expressed on leukocytes, including overexpression on lymphomas and leukemias. We have developed a derivative of BIRT 377, an allosteric inhibitor of LFA-1, which may be chemically tagged without affecting binding. In this study, we modified this derivative, (R)-1-(4-aminobutyl)-5-(4-bromobenzyl) -3-(3,5-dichlorophenyl)-5-methylimidazolidine-2,4-dione (butylamino-NorBIRT), and demonstrated its potential as a noninvasive imaging agent. Methods: Specific binding of fluorescein-labeled butylamino-NorBIRT to both human and murine cells was demonstrated using equilibrium binding and dissociation techniques. A radiometal, lutetium-177 (Lu-177), was incorporated into the butylamino-NorBIRT through 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA) as a chelator. Results: Equilibrium-binding experiments demonstrated that fluorescein-labeled butylamino-NorBIRT specifically binds human and murine LFA-1 with affinity constants of 135 and 186 nM, respectively. Dissociation kinetic experiments demonstrated an off-rate of 0.168/second -1 on murine cells, consistent with the observed affinity constant. Lutetium-177 was used for labeling, with ≥99.99% radiochemical purity and incorporation yield. This radiolabeled derivative exhibited high stability in fetal bovine serum (FBS) at 37°C over 72 hours. 177Lu-DOTA- butylamino-NorBIRT showed a binding affinity of 235 nM to human LFA-1 for equilibrium binding and competitive binding experiments. Conclusions: The radiolabeled DOTA-butylamino-NorBIRT may have potential as a noninvasive imaging or therapeutic agent in both human and mouse models.

AB - Objective: Leukocyte function-associated antigen-1 (LFA-1) is constitutively expressed on leukocytes, including overexpression on lymphomas and leukemias. We have developed a derivative of BIRT 377, an allosteric inhibitor of LFA-1, which may be chemically tagged without affecting binding. In this study, we modified this derivative, (R)-1-(4-aminobutyl)-5-(4-bromobenzyl) -3-(3,5-dichlorophenyl)-5-methylimidazolidine-2,4-dione (butylamino-NorBIRT), and demonstrated its potential as a noninvasive imaging agent. Methods: Specific binding of fluorescein-labeled butylamino-NorBIRT to both human and murine cells was demonstrated using equilibrium binding and dissociation techniques. A radiometal, lutetium-177 (Lu-177), was incorporated into the butylamino-NorBIRT through 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA) as a chelator. Results: Equilibrium-binding experiments demonstrated that fluorescein-labeled butylamino-NorBIRT specifically binds human and murine LFA-1 with affinity constants of 135 and 186 nM, respectively. Dissociation kinetic experiments demonstrated an off-rate of 0.168/second -1 on murine cells, consistent with the observed affinity constant. Lutetium-177 was used for labeling, with ≥99.99% radiochemical purity and incorporation yield. This radiolabeled derivative exhibited high stability in fetal bovine serum (FBS) at 37°C over 72 hours. 177Lu-DOTA- butylamino-NorBIRT showed a binding affinity of 235 nM to human LFA-1 for equilibrium binding and competitive binding experiments. Conclusions: The radiolabeled DOTA-butylamino-NorBIRT may have potential as a noninvasive imaging or therapeutic agent in both human and mouse models.

KW - Butylamino-NorBIRT

KW - Leukocyte function-associated antigen-1

KW - Lutetium-177

KW - Lymphoma

KW - Radionuclide imaging

UR - http://www.scopus.com/inward/record.url?scp=33750982424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750982424&partnerID=8YFLogxK

U2 - 10.1089/cbr.2006.21.418

DO - 10.1089/cbr.2006.21.418

M3 - Article

VL - 21

SP - 418

EP - 426

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 5

ER -